Lead Product(s): CDX-005
Therapeutic Area: Infections and Infectious Diseases Product Name: CDX-005
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
CDX-005, is currently under safety and efficacy studies in animals and appears markedly attenuated compared to wild-type SARS-CoV-2. After successful completion of pre-clinical studies, CDX-005 will be manufactured by the Serum Institute and tested in a Phase I clinical trial.
Lead Product(s): Live-attenuated vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Recipient: Serum Institute of India
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 14, 2020
Codagenix has designed multiple nCoV vaccine candidate genomes using its proprietary deoptimization technology. The vaccine viruses will then be grown and tested in vivo.
Lead Product(s): Respiratory syncytial virus vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Adjuvant Capital
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 13, 2020
The funds will be used to support the further clinical development of Codagenix's live attenuated RSV vaccine for the elderly.